NextCell Pharma AB (“NextCell”) today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company’s proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the central nervous system.
The application was submitted to the Swedish Patent and Registration Agency on August 15 and is formulated to cover the general production of all types of mesenchymal stem cell products derived from multiple donors and cells selected by the selection algorithm. Furthermore, the application describes an expanded number of analyses and potency assays to broaden the protection in the previous application and focuses specifically on stem cells in order to treat diseases and conditions affecting the central nervous system.
The current patent application is the third in order. Already, there are two patent applications, filed in February 2018 and July 2018. The first relates to the company’s selection algorithm that ensures that the most potent cells are selected, while the second relates to a prediction algorithm for predicting whether the patient is susceptible to treatment, i.e. companion diagnostic. with the company’s drug candidate ProTrans.
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
